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ABSTRACT 
Objective: To determine whether inflammatory markers prospectively predict 
depressive symptom severity 12 months later in heart failure (HF) patients.     
Methods: In 30 HF patients we assessed depressive symptom severity by the Beck 
Depression Inventory (BDI) at baseline as well as 12 months later. We measured circulating 
levels of the soluble intercellular adhesion molecule (sICAM)-1, the cytokine interleukin 
(IL)-6 and the acute phase protein C-reactive protein (CRP) at baseline assessment.    
Results: sICAM-1 (r=.38, p=.045) but not CRP or IL-6 correlated with BDI scores 12 
months later. Stepwise multiple linear regression analysis revealed that independent of 
baseline BDI assessment, cardiovascular risk factors, indicators of HF disease severity, and 
medication intake, sICAM-1 significantly predicted BDI scores 12 months later. sICAM-1 
independently explained between 7% (β=.26, p=.040) and 14 % (β=.38, p=.045) of the total 
variance in BDI scores 12 months later.  
Conclusion: The findings from this exploratory analysis suggest that the adhesion 
molecule sICAM-1 is an independent predictor of depressive symptoms 12 months later in 
HF patients. Our prospective findings support the suggested role for inflammation in 
increasing future depressive symptom severity and extend this linkage for the first time to 
HF. 
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 INTRODUCTION 
 A recent hypothesis posits that inflammation can lead to depression and depressive 
symptoms in vulnerable patients (Dantzer et al., 2008). Heart failure (HF) is a major public 
health concern associated with both increased incidence of depressive symptoms and clinical 
depression as well as elevated pro-inflammatory activities indicated by levels of adhesion 
molecules or inflammatory cytokines (Mari et al., 2002; Parissis et al., 2005; Rutledge et al., 
2006; York et al., 2008). Indeed, we and others report cross-sectional associations between 
inflammation and depressive symptoms or clinical depression in HF patients (Moorman et al., 
2007; Parissis et al., 2004; Redwine et al., 2007). However, although elevated biomarkers of 
inflammation were shown to precede the onset of depressed mood in an aged non-HF 
population (van den Biggelaar et al., 2007), a prospective relationship between inflammation 
and depressive symptoms has not yet been studied in HF.   
The purpose of this exploratory study was to determine whether different types of 
inflammatory markers (i.e. an adhesion molecule, an inflammatory cytokine, and an acute 
phase protein) prospectively predict depressive symptom severity 12 months later in HF 
patients. We controlled for a variety of potential confounders including cardiovascular risk 
factors, indicators of HF severity, and medication intake. 
 
 
METHODS 
Study participants 
The study sample consisted of 30 patients diagnosed with HF. Patients were recruited 
from the San Diego Veterans Affairs Medical Center and the University of California, San 
Diego Medical Center Heart Failure Program as part of a larger study on associations 
between depression, cellular adhesion and inflammation.  
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Inclusion criteria included age between 30 - 85 years, NYHA classes II through IV, 
symptoms of HF for at least 3 months which have been optimally treated with beta-blockers, 
diuretics and ACE inhibitors, and systolic dysfunction defined by an ejection fraction ≤ 45% 
or diastolic dysfunction, hypertension < 180/110 mm Hg, and men of all ethnicities and races. 
Exclusion criteria included recent myocardial infarction (1 month), recent stroke or 
significant cerebral neurological impairment, severe chronic obstructive pulmonary disease, 
inability to exercise and psychiatric illness other than depression and comorbid anxiety. 
Patients were instructed to abstain from taking aspirin for 24 hours prior to the testing 
session. Left ventricular ejection fraction (LVEF) was assessed by echocardiography as part 
of the patient’s routine medical evaluation. To assess functional capacity in the patients, we 
used the six-minute walk-test (O'Keeffe et al., 1998). Resting BP was taken using an 
automated BP monitor (Dinamap Compact BP® monitor, Critikon, Tempa, FL). 
The protocol was approved by the UCSD Institutional Review Board, and participants 
gave written informed consent. The study was carried out in accordance with the Declaration 
of Helsinki principles. 
 
Depressive symptom severity                                                                                                                               
Depressive symptom severity was assessed with the 21-item Beck Depression 
Inventory (BDI) (Beck, 1978) (baseline) and 12 months later. In a subsample of 16 patients, 
we additionally obtained an 18 months follow-up BDI. The BDI scores ≥ 10 indicate possible 
clinical depression, assesses symptoms related to sadness, feelings of guilt, perceptions of 
self-worth, suicidal ideation, and changes in appetite and body weight, among other 
characteristics. Subjects with scores ≥ 10 on the initial BDI assessment were administered a 
modified Structured Clinical Interview for DSM-IV (SCID) (American Psychiatric 
Association, 1994) to evaluate for possible major depressive disorder (MDD). If suspected of 
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having MDD they were presented with a list of options and referred to their treating 
physician.  
 
Blood sampling and biochemical analyses 
Blood samples were drawn via venous catheter around 9:00 am at the UCSD General 
Clinical Research Center. Participants had abstained from food and drink (other than water) 
for two hours before blood sampling, and from physical exercise, alcohol and caffeinated 
beverages starting the evening before the blood sampling day. Blood was drawn into EDTA-
coated vacutainer tubes (BD Biosciences, San Jose, CA, USA) and centrifuged for 10 min at 
300g and 4°C. Plasma was stored at –80°C until analysis. 
We selected a representative panel of inflammatory markers based on the existing 
literature (2-5). Circulating levels of soluble intercellular adhesion molecule 1 (sICAM-1) 
and interleukin-6 (IL-6) were determined following previous methods using enzyme-linked 
immunosorbent assay (ELISA) kits (R&D Systems, Mpls., MN) (Mills et al., 2000; Rehman 
et al., 1997). C-reactive protein (CRP) was determined in plasma using the high sensitivity 
Denka-Seiken assay (Roberts et al., 2001). The precision and sensitivity performance values 
were: sICAM-1, intra-assay CV is 4.6%, inter-assay CV is 6.6, sensitivity is <0.35 ng/ml; IL-
6 intra-assay CV is 2.2%, inter-assay CV is 3.9, sensitivity is <0.71 pg/ml; CRP intra-assay 
CV is < 1.0%, inter-assay CV is 1.6, sensitivity is <0.05 mg/l. To minimize intra-assay error 
variance, all samples from an individual subject were analyzed in the same run. 
 
Statistical Analyses 
All calculations were performed using SPSS Inc. (v11.0.1) software packages (SPSS, 
Chicago, IL). Data are presented as mean ± SEM. Results were considered statistically 
significant at the p≤ .05 level and all tests were two-tailed. In case of missing data, cases 
were excluded listwise. We calculated mean arterial pressure (MAP) from resting BP 
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readings (1/3 systolic BP + 2/3 diastolic BP) and body mass index (BMI) was calculated by 
the formula: weight in kg / (height in m)2. 
Power analyses (Faul, 2007) revealed that the optimal total sample size to predict a 
large effect size of f2 = 0.35 in regression analyses with a power of 0.85 using a maximum of 
6 predictors was 29.  
We calculated bivariate correlations between the 12-months BDI score and the three 
inflammatory parameters.  
To assess the prospective association of inflammatory measures with depressive 
symptom severity, we performed separate hierarchical linear regression analyses using the 
12-months BDI score as the dependent variable and each of the three inflammatory measures 
as the independent variable while controlling for baseline BDI. We also controlled for the 
interaction between baseline BDI and significant inflammatory predictors. Next, to identify 
potential confounders of significant inflammatory predictors we repeated the initial 
regression model(s) and tested in further regression steps for potential confounders: In a first 
step, we controlled for an a-priori defined set of demographic and cardiovascular factors 
including age, gender, BMI, and MAP. In a second step, we controlled for indicators of HF 
severity, namely LVEF and meters walked in the 6-min walk test. Third, we controlled for 
medication intake. To reduce statistical over-controlling, given our sample size, we entered 
medication in two blocks (block 1: 4 pharmaceuticals, block 2: 5 pharmaceuticals). 
Noteworthy, to reduce statistical over-controlling given our sample size (Babyak, 2004) we 
only entered significant predictors of one regression step (p<.05) into the next regression 
step(s) by means of forced inclusion. Non-significant predictors were excluded. We 
moreover tested the predictive value of our regression model on prediction of BDI scores at 
18 months. All regression parameters were Z-transformed prior to analyses rendering 
variables centered to the mean with a standard deviation of 1, particularly to allow 
computation of interaction terms. 
   6
 
 
 
RESULTS 
Table 1 presents the biological and medical characteristics of the 30 HF patients 
studied. Most of the patients were NYHA class II and were taking ACE inhibitors, beta-
blockers, and diuretics, and a high percent of patients was taking statins and digoxin. 
Although mean BDI scores remained similar from baseline (11.4, SEM ± 1.6) to 12 months 
later (11.0, SEM ± 1.8),  individual BDI scores were increased in 11 patients, decreased in 15 
patients, and unchanged in 4 patients. At baseline, according to clinical interview, none of the 
study patients were determined to have major depressive disorder. We did not perform 
clinical interviews after 12 months to determine major depressive disorder. Noteworthy, 8 
patients had a BDI score of ≥ 17 after 12 months.  
As depicted in Table 2, sICAM-1 was the only inflammatory measure that correlated 
with the 12-months BDI-score.  
The initial regression models revealed that among the total study group, only sICAM-
1 (initial regression model, Table 3) but not CRP (p=.46) or IL-6 (p=.15) significantly 
predicted BDI 12 months later. Baseline BDI was controlled. Separate recalculation of these 
initial regression models in the 11 subjects with increasing BDI scores confirmed our initial 
findings: Only sICAM-1 (β=.52, p=.022, R2 change=.24), but not CRP (p=.78) or IL-6 
(p=.90) were prospectively associated with BDI at 12 months. In subjects with CRP level > 3 
mg/L (N=11), higher CRP predicted higher BDI 12 months later independent of baseline 
BDI (β=.36, p=.05, R2 change=.13).  
Table 3 presents the results of the multiple linear regression analysis for the 
significant inflammatory predictor sICAM-1. Through all steps of the analysis, sICAM-1 and 
BDI baseline scores but none of the other entered parameters (p’s > .32) emerged as 
significant predictors of depressive symptom severity as measured by BDI 12 months later. 
sICAM-1 alone independently explained between 7 and 14 % of the total variance in BDI 
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scores (R2 change scores, Table 3). The final model including only significant predictors 
corresponded to the initial regression model and consisted of sICAM-1 and BDI score at 
baseline and explained 62% of the total variance in BDI scores at 12 months with sICAM-1 
independently explaining 7%. As statins are known to have anti-inflammatory effects we 
repeated our initial sICAM-1 regression model separately in patients treated with statins 
compared to those not treated with statins as post-hoc test. In the group without statins, 
sICAM-1 strongly predicted BDI at 12 months (β=.46, p=.040, R2 change=.18) whereas it 
did not in the group with statins (p=.70). We also performed the full multiple linear 
regression models with all potential confounders for CRP and IL-6 and these models were 
not significant. 
A subset of 16 patients also completed the BDI at 18 months. For this subset of 
patients, BDI scores were as follows: baseline: 9.9 (SEM ± 2.2); 12 months: 10.1 (SEM ± 
2.3); 18 months: 10.4 (SEM ± 2.2). When regressing BDI score at 18 months by entering 
sICAM-1 and BDI baseline as predictors, results remained similar: sICAM-1 independently 
explained 10% (β=.37) of the total variance in BDI score at 18 months, but however not in a 
statistically significant way (p=.10), probably due to the smaller sample size. The total model 
explained 58% of the total variance in BDI 18 months later (p=.004). 
 
DISCUSSION 
We found that in HF patients higher sICAM-1, but not IL-6, prospectively predicted 
higher depressive symptom severity 12 months later. Independent of baseline BDI, higher 
CRP also predicted higher depressive symptom severity 12 months later in those patients 
with slightly elevated CRP levels (> 3 mg/L). The association between sICAM-1 and 
depressive symptom severity 12 months later was independent of baseline depressive 
symptom severity, cardiovascular risk factors, HF severity, and medication intake. Separate 
reanalyses in patients treated with and without statins suggest that the observed sICAM-1 
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effect is mostly carried by the non-statin users. Therefore, it can be speculated that the effect 
would have been stronger if statin use had been excluded from study participation. The 
findings implicate, limited to HF patients, that sICAM-1 (and possibly CRP) might play a 
role in future depressive symptom severity. In this cohort of predominately NYHA II 
patients, during the 12 months follow-up, depressive symptoms increased in 37% of the 
patients, decreased in 50%, and were unchanged in 13%. Given that depressive symptoms are 
associated with adverse outcomes in HF patients (Rutledge et al., 2006) our findings might 
be of clinical relevance. sICAM-1 expression can be induced by inflammatory cytokines 
(Bevilacqua, 1993). In the myocardium of HF patients, upregulation of ICAM-1 and the 
presence of macrophages expressing inflammatory cytokines have been observed (Deswal et 
al., 2001). sICAM-1 indicates enhanced expression of adhesion molecules on the cell surface 
and has been suggested to reflect increased inflammation (Blann et al., 2002). The finding of 
inflammation predicting future depressive symptoms in vulnerable patients like HF patients 
is consistent with a very recent review by Dantzer et al. (Dantzer et al., 2008). As an 
underlying mechanism of this association, inflammatory cytokines (i.e. tumor-necrosis-
factor-α and interferon-γ) have been proposed to induce a reduction in serotonin synthesis by 
increasing indoleamine 2,3 dioxygenase (IDO)-induced reduction of tryptophan to 
kynurenine (Dantzer et al., 2008). Although we did not observe an association between the 
cytokine IL-6 and depressive symptom severity, other inflammatory cytokines and their 
actions may play a role in the observed association between sICAM-1 and future depressive 
symptom severity in HF patients. Main limitations of the study are that we did not investigate 
control subjects or other heart conditions. In addition, we assessed inflammatory markers 
only once and thus could not investigate the possibility of depression predicting 
inflammation. In sum, our findings suggest a role for inflammatory measures in increasing 
future depressive symptom severity in HF patients which could be associated with clinical 
endpoints. 
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Table 1. Sociodemographic and Medical Characteristics of the Study Subjects  
 
BDI score  
    Baseline 11.4 ± 1.6 (0-31) 
    12 months 11.0 ± 1.8 (0-34) 
Inflammatory markers (baseline)  
     sICAM-1 [ng/ml] 
     CRP [mg/L] 
315.3 ± 18.6 (120-527) 
 
3.16 ± .54 (.52-14.8) 
     IL-6 [pg/ml] 3.79 ± .37 (1.36-9.75) 
Age [years] 60.8 ± 2.5 (34-81) 
Body mass index [kg/m2] 31.9 ± 1.8 (20.0-59.0) 
Gender [men] 86.7 % 
Mean arterial BP [mmHg] 85.4 ± 2.6 (59.0-107.6) 
Cigarettes per day 5.2 ± 2.5 (0-60) 
Current smokers  22.2 % 
CHF severity 
     Ejection fraction [%] 
 
31.2 ± 1.7 (14-54) 
    6-minute walk test [meter] 331.5 ± 20.9 (100-624) 
    NYHA classification II  86.7 % 
    NYHA classification III  13.3 % 
Concomitant disease  
    Diabetes mellitus  35.7 % 
Medication   
    ACE-blocking agents 78.6 %  
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    Beta blockers  96.6 % 
    CCB  10.7 % 
    Statins  57.1 % 
    Aspirin  57.1 % 
   Diuretics  85.7 % 
   Anti-arrhythmics  21.4 % 
   Warfarin 8.5 % 
   Digoxin  57.1 % 
Data are presented as mean ± standard error of means (range) or percentage value, sICAM-
1, soluble intercellular adhesion molecule 1; CRP, C-reactive protein; IL-6, interleukin-6; 
BP, blood pressure; BDI: Beck Depression Inventory, CCB: Calcium channel blockers 
 
 
 Table 2.  Correlation Coefficients (r) between inflammatory measures and BDI 
scores in HF patients 
Inflammatory 
measures 
BDI score at 
baseline 
BDI score after 12 
months 
  BDI score after 18 
months 
sICAM-1  .16, p = .41 .38, p = .045* .63, p = .009** 
CRP  .06, p = .77 .14, p = .47 .29, p = .27 
IL-6  .35, p = .07 .06, p = .77 .14, p = .60 
Values are means ± SEM; sICAM-1, soluble intercellular adhesion molecule 1; CRP, C-
reactive protein; IL-6, interleukin-6; *, p<.05; **, p<.01  
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Table 3. Hierarchical multiple regression predictors of BDI scores at 12 months by  
sICAM-1 
Additionally entered variables per 
regression step 
Significant individual predictor variables with 
standardized β-coefficient, p-value and R2 
change 
Model 
R2  
Initial regression model 
   BDI baseline 
   sICAM-1 
 
BDI baseline (.70, <.001, .48), 
sICAM-1 (.26, .040, .07) 
 
 
.62 
  sICAM-1–by-BDI baseline  BDI baseline (.66, <.001, .36), 
sICAM-1 (.29, .033, .08) 
 
.63 
Control variable testing Step 1 
   Age, gender, BMI, MAP 
 
BDI baseline (.70, <.001, .38), 
sICAM-1 (.30, .047, .08) 
 
 
.66 
 Control variable testing Step 2 
6-minute walk test [m], ejection   
fraction [%] 
 
BDI baseline (.71, <.001, .46), 
sICAM-1 (.28, .043, .08) 
 
 
.63 
   Control variable testing Step 3a 
Medication intake block 1 
(ACE-blocker, Beta blocker, 
CCB, statins) 
 
BDI baseline (.65, <.001, .33), 
sICAM-1 (.30, .041, .08) 
 
 
.66 
   Control variable testing Step 3b 
Medication intake block 2 
(Aspirin, diuretics, anti-
arrhythmics, warfarin, 
digoxin) 
 
BDI baseline (.55, .005, .21),  
sICAM-1 (.35, .045, .10) 
 
 
.63 
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sICAM-1, soluble intercellular adhesion molecule 1; BDI: Beck Depression Inventory; 
BMI, body mass index; MAP, mean arterial blood pressure; CCB: Calcium channel 
blockers 
